Management of equine sarcoids.

Summary

# Editorial Summary: Management of Equine Sarcoids Equine sarcoids represent the most prevalent skin tumour in horses, driven by fibroblastic proliferation secondary to bovine papillomavirus infection—predominantly types 1 and 2—making their management a significant clinical and economic concern for practitioners. Although these lesions do not metastasise, their locally invasive and aggressive nature frequently compromises welfare, interferes with saddle fit and bridle placement, and substantially diminishes athletic performance and market value. Hollis's 2023 review synthesises the evidence base for commonly employed treatment modalities, revealing considerable heterogeneity in reported efficacy and the level of scientific rigour underpinning each approach. The absence of a universally effective treatment underscores the need for individualised case management, with practitioners required to weigh available options against lesion location, size, and the horse's intended use. This comprehensive evaluation of therapeutic outcomes should inform clinical decision-making and highlight areas where further robust comparative trials are warranted to improve standardisation of sarcoid management protocols.

Read the full abstract on PubMed

Key Findings

• •Sarcoids are the most common cutaneous neoplasm in horses, caused by bovine papillomavirus types 1 and 2 infection
• •Although sarcoids do not metastasize, they are locally invasive and aggressive with significant welfare and performance implications
• •No single treatment is universally successful for equine sarcoids, with multiple therapeutic approaches showing varying levels of scientific evidence and success rates

Conditions Studied

Tags